Wegovy gets CDSCO approval: Can Novo Nordisk’s semaglutide change fatty liver treatment?
In a major development in the healthcare sector, the Central Drugs Standard Control Organisation (CDSCO) has approved Novo…
Novo Nordisk’s Wegovy wins India nod for fatty liver disease; Emcure to distribute
Novo Nordisk has secured regulatory approval for Wegovy as the first and only GLP-1 receptor agonist for the…